On the 4th, LG Chem announced it will be releasing its new antidiabetic combination drug ‘Zemidapa Tab’ on the 8th.

Zemidapa is a fixed-dose combination of the DPP-4 inhibitor class market leader Zemiglo (gemigliptin) and SGLT-2 inhibitor class market leader dapagliflozin (Product name: Forxiga). Zemidapa is the only option that offers a combination of the said two ingredients.

According to the amendment made to the reimbursement of antidiabetic combination therapies that are applied from this month, Zemiglo will be allowed to be additionally prescribed to patients taking metformin and SGLT-2 inhibitors whose glucose level is not properly controlled. Zemidapa will be allowed to be p